Provided by Tiger Trade Technology Pte. Ltd.

MannKind

2.44
-0.0300-1.21%
Post-market: 2.440.00000.00%19:59 EDT
Volume:6.29M
Turnover:15.45M
Market Cap:749.25M
PE:122.00
High:2.59
Open:2.54
Low:2.39
Close:2.47
52wk High:6.51
52wk Low:2.39
Shares:307.07M
Float Shares:300.98M
Volume Ratio:0.84
T/O Rate:2.09%
Dividend:- -
Dividend Rate:- -
EPS(TTM):0.0200
EPS(LYR):0.0200
ROE:32.74%
ROA:4.91%
PB:-14.68
PE(LYR):122.00

Loading ...

MannKind’s Strategic Initiatives and Partnerships Signal Strong Growth Potential

TIPRANKS
·
Nov 06, 2025

MannKind’s Strong Financial Performance and Growth Prospects Drive Buy Rating

TIPRANKS
·
Nov 06, 2025

Stock Track | MannKind (MNKD) Surges 10.86% on Strong Q3 Results, FDA Acceptance of Afrezza Pediatric Application

Stock Track
·
Nov 05, 2025

Biopharma MannKind's Q3 revenue up 17%

Reuters
·
Nov 05, 2025

MannKind reports Q3 EPS 7c, consensus 3c

TIPRANKS
·
Nov 05, 2025

Stock Track | MannKind Soars 5.84% Pre-Market on Strong Q3 Results, Beating EPS and Revenue Estimates

Stock Track
·
Nov 05, 2025

Stock Track | MannKind (MNKD) Soars 5.84% Pre-Market on Strong Q3 Results, Beating EPS Estimates by 233%

Stock Track
·
Nov 05, 2025

MannKind Corporation reports third quarter 2025 revenues of $82.1 million

Reuters
·
Nov 05, 2025

BRIEF-MannKind Q3 Operating Income USD 18.896 Million

Reuters
·
Nov 05, 2025

MannKind Q3 Pretax Profit USD 7.781 Million

THOMSON REUTERS
·
Nov 05, 2025

MannKind Q3 Basic EPS USD 0.03

THOMSON REUTERS
·
Nov 05, 2025

MannKind Corporation to Hold 2025 Third Quarter Financial Results Conference Call on November 5, 2025

GlobeNewswire
·
Oct 30, 2025

Assessing MannKind (MNKD) Valuation Following FDA Acceptance of Afrezza Pediatric Application

Simply Wall St.
·
Oct 20, 2025

MannKind’s Afrezza: Promising Expansion and Growth Potential with FDA sBLA Acceptance

TIPRANKS
·
Oct 13, 2025

MannKind's Biologics License Application for Diabetes Treatment Afrezza Accepted by FDA

MT Newswires Live
·
Oct 13, 2025

BRIEF-Mannkind Announces US FDA Accepts For Review Its sBLA For Inhaled Insulin

Reuters
·
Oct 13, 2025

MannKind Corp - Afrezza Sbla Pdufa Date Set for May 29, 2026

THOMSON REUTERS
·
Oct 13, 2025

MannKind Announces U.S. FDA Accepts for Review Its Supplemental Biologics License Application (Sbla) for Inhaled Insulin (Afrezza) in Children and Adolescents Aged 4-17 Years Living With Diabetes

THOMSON REUTERS
·
Oct 13, 2025

MannKind Price Target Maintained With a $11.00/Share by HC Wainwright & Co.

Dow Jones
·
Oct 13, 2025

MannKind (MNKD) Receives a Buy from Leerink Partners

TIPRANKS
·
Oct 10, 2025